Testosterone recovery and changes in bone mineral density after stopping long‐term luteinizing hormone‐releasing hormone analogue therapy in osteoporotic patients with prostate cancer

Abstract

Osteoporotic patients, after stopping LHRH analogues, continue to have suppressed levels of testosterone which have a detrimental effect on bone mineral density. We therefore would not advocate conversion to antiandrogen monotherapy to improve bone density, and suggest alternative therapeutic intervention e.g. bisphosphonate therapy, for these patients.